Corcept Therapeutics, Inc. (CORT)
116.23
+2.20
(+1.93%)
USD |
NASDAQ |
Oct 02, 16:00
116.23
0.00 (0.00%)
After-Hours: 20:00
Corcept Therapeutics Gross Profit Margin (Quarterly) : 98.41% for June 30, 2026
Gross Profit Margin (Quarterly) Chart
Historical Gross Profit Margin (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 98.41% |
| March 31, 2026 | 98.25% |
| December 31, 2025 | 98.74% |
| September 30, 2025 | 97.79% |
| June 30, 2025 | 98.23% |
| March 31, 2025 | 98.47% |
| December 31, 2024 | 98.37% |
| September 30, 2024 | 98.43% |
| June 30, 2024 | 98.46% |
| March 31, 2024 | 98.27% |
| December 31, 2023 | 98.61% |
| September 30, 2023 | 98.67% |
| June 30, 2023 | 98.66% |
| March 31, 2023 | 98.69% |
| December 31, 2022 | 98.56% |
| September 30, 2022 | 98.68% |
| June 30, 2022 | 98.73% |
| March 31, 2022 | 98.67% |
| December 31, 2021 | 98.63% |
| September 30, 2021 | 98.67% |
| June 30, 2021 | 98.49% |
| March 31, 2021 | 98.40% |
| December 31, 2020 | 98.54% |
| September 30, 2020 | 98.59% |
| June 30, 2020 | 98.61% |
| Date | Value |
|---|---|
| March 31, 2020 | 97.99% |
| December 31, 2019 | 98.37% |
| September 30, 2019 | 98.22% |
| June 30, 2019 | 98.09% |
| March 31, 2019 | 98.09% |
| December 31, 2018 | 97.64% |
| September 30, 2018 | 97.97% |
| June 30, 2018 | 98.15% |
| March 31, 2018 | 97.96% |
| December 31, 2017 | 97.83% |
| September 30, 2017 | 97.72% |
| June 30, 2017 | 97.82% |
| March 31, 2017 | 97.66% |
| December 31, 2016 | 97.64% |
| September 30, 2016 | 96.93% |
| June 30, 2016 | 97.84% |
| March 31, 2016 | 97.49% |
| December 31, 2015 | 97.57% |
| September 30, 2015 | 98.07% |
| June 30, 2015 | 96.33% |
| March 31, 2015 | 97.01% |
| December 31, 2014 | 97.14% |
| September 30, 2014 | 96.77% |
| June 30, 2014 | 96.33% |
| March 31, 2014 | 96.05% |
Gross Profit Margin Definition
Gross Profit Margin is calculated using Gross Profit/Revenue. This metric measures the overall efficiency of a company in being able to turn revenue into gross profit and doing this by keeping cost of goods sold low. An analyst looking at gross profit margin might look for a higher gross profit margin relative to other comparable companies as well as a gross profit margin that is growing.
Gross Profit Margin (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Gross Profit Margin (Quarterly) Benchmarks
| Eli Lilly & Co. | 85.78% |
| Pfizer Inc. | 62.94% |
| Aclaris Therapeutics, Inc. | 10.80% |
| Bristol Myers Squibb Co. | 67.95% |
| Liquidia Corp. | 93.10% |
Gross Profit Margin (Quarterly) Related Metrics
| Return on Equity | 8.32% |
| Return on Assets | 6.50% |
| Return on Invested Capital | 8.22% |
| Profit Margin (Quarterly) | 16.45% |
| Operating Margin (Quarterly) | 16.12% |
| Return on Net Operating Assets | 52.69% |